Surgalign Holdings downgraded by Craig Hallum with a new price target
$SRGA
Industrial Specialties
Health Care
Craig Hallum downgraded Surgalign Holdings from Buy to Hold and set a new price target of $1.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2021 | $1.50 | Buy → Hold | Craig Hallum |
Craig Hallum downgraded Surgalign Holdings from Buy to Hold and set a new price target of $1.50
BTIG Research initiated coverage of Surgalign Holdings with a rating of Buy and set a new price target of $4.00
BTIG Research initiated coverage of Surgalign with a rating of Buy
DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 437-3179 (U.S.) or 862-298-0702 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conference call will be available
Expands Xtant's Product Offering with the Leading PMA-Approved Intralaminar Stabilization Device Strengthens Surgalign's Balance Sheet as it Embarks on its Digital Health Strategy BELGRADE, Mont. and DEERFIELD, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, and Surgalign Holdings, Inc., (NASDAQ:SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced the completion of a transaction between the companies. On February 28, 2023, Xtant Medical and Surgalign entered
DEERFIELD, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 third quarter ended September 30, 2022. 2022 Third Quarter Corporate Highlights: Two new clinical sites in Ohio utilize the HOLO PortalTM surgical guidance system.FDA 510(k) clearance of the Cortera™ Spinal Fixation System, the first organically designed product by Surgalign.Expansion of the Fortilink® product portfolio with TiPlus™ technology products.Settlements with Resolve Surgical Technologies and RTI Surgical, Inc., and with
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)